3 recruiting, 2 not yet recruiting, 1 active not recruiting. 2 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 2 |
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Ivonescimab Injection: new trials by email Literature Review of Ivonescimab Injection trials Research Report on Ivonescimab Injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants. ALK201 for injection, Ivonescimab Injection - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | Not yet recruiting | Shanghai Allink Biotherapeutics Co., Ltd. | 156 | 2026-08-20 | 2026-08-03 |
| Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants. ALK202 for injection, Osimertinib Mesylate Tablets, Ivonescimab Injection - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | Not yet recruiting | Shanghai Allink Biotherapeutics Co., Ltd. | 252 | 2026-06-30 | 2026-05-22 |
| Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study Ivonescimab Injection - Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC, EGFR Mutation-negative and ALK Rearrangement-negative | Recruiting | Guangdong Association of Clinical Trials | 265 | 2026-01-20 | 2026-10-21 | |
| Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC JSKN016, Carboplatin, Furmonertinib Mesylate - Advanced Non-small Cell Lung Cancer | Phase 1 | Recruiting | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 288 | 2025-04-02 | 2026-03-30 |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 Ivonescimab Injection, Pembrolizumab Injection - Non-Small Cell Lung Cancer | Phase 3 | Recruiting | Summit Therapeutics | 780 | 2025-02-27 | 2026-09-18 |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients Ivonescimab Injection, Pembrolizumab Injection - Non-Small Cell Lung Cancer | Phase 3 | Active not recruiting | Summit Therapeutics | 1600 | 2023-10-26 | 2026-10-08 |
Carcinoma, Non-Small-Cell Lung (5) · Neoplasm Metastasis (1)
Shanghai Allink Biotherapeutics Co., Ltd. (2) · Summit Therapeutics (2) · Guangdong Association of Clinical Trials (1) · Jiangsu Alphamab Biopharmaceuticals Co., Ltd (1)
China (4) · Belgium (2) · Canada (2) · France (2) · Germany (2) · Greece (2) · Italy (2) · Japan (2) · Mexico (2) · Poland (2) · Serbia (2) · Spain (2) · Turkey (Türkiye) (2) · United States (2) · Hungary (1)